Microbiology

Enveda Biosciences Announces Therapeutic Advisory Board Chaired by Nicholas Saccomano, Ph.D.

Retrieved on: 
Wednesday, January 10, 2024
Technology, Clinical Trials, Professional Services, Software, Biotechnology, Health, Pharmaceutical, Data Management, Artificial Intelligence, Patient, Fibrosis, Consultant, Chemistry, REAL, Pharmacology, AI, Research fellow, Microbiology, Drug discovery, Pfizer, Immunology, Duke University, Drug development, TAB, Scripps Research, Inflammation, Human, Plant, Research, Nature, SVP, Pharmaceutical industry

Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.

Key Points: 
  • Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.
  • “This is an incredibly exciting time for Enveda as we launch our first trials for multiple lead assets and transition into a clinical-stage company.
  • The formation of the TAB marks a significant milestone for Enveda Biosciences as they advance their first assets for a range of inflammatory and neurosensory conditions.
  • Founded in 2019, the company plans to launch at least two clinical trials in 2024.

Dr. Adam Perlman, Former Medical Director at Mayo Clinic, Joins Pendulum Therapeutics as Chief Medical Officer

Retrieved on: 
Tuesday, January 9, 2024
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Alternative medicine, Biochemistry, Stanford University, Patient, Overalls, Research, Associate, Internal medicine, Multimedia, Johns Hopkins University, Science, Wellness, Sequoia Capital, Meritech Capital Partners, Medicine, Duke University Health System, Prediabetes, Mayo Clinic, FACP, Clinical professor, Duke University, PGC, IND, Cornell University, Conditional sentence, FDA, Doctor of Philosophy, Khosla Ventures, MPH, Clinical trial, Microbiology, Medical device

- Today, Pendulum Therapeutics , the leading microbiome biotech company pioneering the next frontier of metabolic health, announced that former Mayo Clinic Medical Director and Executive Director for Integrative Medicine at Duke University, Adam Perlman, MD, MPH, FACP, has joined the company as Chief Medical Officer.

Key Points: 
  • - Today, Pendulum Therapeutics , the leading microbiome biotech company pioneering the next frontier of metabolic health, announced that former Mayo Clinic Medical Director and Executive Director for Integrative Medicine at Duke University, Adam Perlman, MD, MPH, FACP, has joined the company as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240109713201/en/
    Dr. Perlman, Chief Medical Officer at Pendulum Therapeutics (Photo: Pendulum Therapeutics)
    As Chief Medical Officer at Pendulum, he will oversee the company’s clinical research portfolio, working internally and with academic collaborators to uncover new insights and inform the development of new products that will deliver strong clinical efficacy and outcomes for consumers.
  • Dr. Perlman saw first hand the efficacy of Pendulum probiotics in his practice, observing benefits in his patients with pre-diabetes and type 2 diabetes.
  • Berry joined Pendulum’s all-star lineup of investors, including Sequoia Capital, Meritech Capital, True Ventures, Khosla Ventures and the Mayo Clinic.

NOW® Consumer Survey Unlocks Top Wellness and Health Priorities For 2024

Retrieved on: 
Tuesday, January 9, 2024
Nutrient, Intertek, Sleep, Research, National Organic Program, ISO 17025, Health, ALL, DNA, Pesticide, Caffeine, WADA, Memory, GMP, Good manufacturing practice, DNA profiling, Vitamin D, Food, Disease, Safety, NOW, Quality control, Dietary supplement, Liver, FDA, RDN, Tyrosine, Iodine, Microbiology

BLOOMINGDALE, Ill., Jan. 9, 2024 /PRNewswire/ -- It's no surprise that packed schedules and never-ending to-do lists weigh heavily on people's health, and the need for energy support to get through each day is a priority. In fact, a recent consumer survey commissioned by leading natural products manufacturer NOW® (Suzy.com, October 2023) revealed nearly half of respondents (48%) are looking for supplements to bolster their energy levels.  In addition to increased energy, respondents cited better sleep (35%), improved stress and mood support (30%) and cardiovascular/heart health support (26%) were top wellness priorities and opportunities to find quality supportive supplements.

Key Points: 
  • In addition to increased energy, respondents cited better sleep (35%), improved stress and mood support (30%) and cardiovascular/heart health support (26%) were top wellness priorities and opportunities to find quality supportive supplements.
  • Blatner recommends some NEW supplements from NOW to support consumers' stated wellness priorities.
  • *
    Improved Cardiovascular Function/Heart Health*: NOW® Heart Health Probiotic features Lactobacillus reuteri LRC™, the first heart health probiotic with scientific backing.
  • Do research to confirm any experts promoting the brand on social or other channels are legit and carry meaningful credentials within the health and wellness space.

HARDY DIAGNOSTICS MAKES GENEROUS DONATION TO A LOCAL HOSPITAL FOR SPECIALIZED LABORATORY EQUIPMENT

Retrieved on: 
Tuesday, January 9, 2024
Laboratory, Hospital, Central Coast, MD, Medical director, Hardy Diagnostics, Pathology, Microbiology, Bacteria, Disease, FDA, Organization, Fungus, Diagnosis, Medical device

SANTA MARIA, Calif., Jan. 9, 2024 /PRNewswire/ -- Microbiology device manufacturer Hardy Diagnostics, made a generous donation to the Marian Regional Medical Center Foundation to support the purchase of advanced identification equipment in the hospital's laboratory. The donation of $289,000 has allowed the lab to purchase highly specialized bacteria and fungi identification equipment not previously available on the Central Coast of California. The equipment will play a vital role in the rapid diagnosis of disease.

Key Points: 
  • SANTA MARIA, Calif., Jan. 9, 2024 /PRNewswire/ -- Microbiology device manufacturer Hardy Diagnostics, made a generous donation to the Marian Regional Medical Center Foundation to support the purchase of advanced identification equipment in the hospital's laboratory.
  • The donation of $289,000 has allowed the lab to purchase highly specialized bacteria and fungi identification equipment not previously available on the Central Coast of California.
  • Donation allows local lab to purchase highly specialized bacteria and fungi identification equipment.
  • Following the ceremony, Jay Hardy and Andre Hsiung, Hardy's Chief Scientific Officer, spoke to the laboratory personnel about Hardy Diagnostics' humble beginnings and its rich history of helping people live healthier lives since 1980.

Global In Vitro Diagnostic (IVD) Procedure Volumes Report 2023-2028: The Gold Standard for Sizing Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Health, Other Health, Research, Chemistry, Microbiology, Histology, IVD

The "In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In vitro diagnostic (IVD) test volumes are the gold standard for sizing the market opportunity for new entrants with diagnostic products, and they can be useful for existing product marketers.
  • The market analysis in the report saves time with calculations and estimates of both the existing number of procedures for scores of diagnostic tests and the future potential.
  • Data statistics appearing in this report correlate to IVD procedures based on commercially sold and distributed tests.

Breakout Ventures Announces Key Promotions and Expands Leadership Team

Retrieved on: 
Thursday, January 4, 2024
Technology, Biotechnology, Nanotechnology, Health, Finance, Pharmaceutical, Professional Services, Oncology, Research, Medical Devices, Software, Science, Data Management, Clinical Trials, Biology, Associate, Ecosystem, Community, Microbiology, CFO, Partner, Regeneration, Chemistry, Chief of staff, Ewing Marion Kauffman Foundation, Georgia Tech, Doctor of Philosophy, General counsel, Investment, Organization, Breakout, Synthetic biology, Cryptocurrency

Breakout Ventures , the home for creative bioscience entrepreneurs, today announced the promotion of Dana Watt, Ph.D. to Partner and Nima Ronaghi, Ph.D. to Principal.

Key Points: 
  • Breakout Ventures , the home for creative bioscience entrepreneurs, today announced the promotion of Dana Watt, Ph.D. to Partner and Nima Ronaghi, Ph.D. to Principal.
  • “Dana and Nima play vital roles in the sourcing and due diligence of new investments, as well as the ongoing support of portfolio companies,” said Julia Moore, Managing Partner, Breakout Ventures.
  • She has led due diligence on key Breakout investments including Canaery, Phantom Neuro, and Vitra Labs.
  • In 2021, Nima joined Breakout Ventures full-time as an Associate, using his scientific background to identify and support companies at the intersection of technology, biology, and chemistry.

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

Retrieved on: 
Thursday, January 4, 2024
KRX, Samsung, Microbiology, CDMO, Samsung Biologics, Automation, Growth

“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.

Key Points: 
  • “Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems.
  • “The Growth Direct® improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”
    Global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges.
  • It is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.
  • To learn more about the Company and the Growth Direct® platform please visit: Rapid Micro Biosystems .

Laboratory Economics Issues Market Research Report on the U.S. Clinical Laboratory Testing Market

Retrieved on: 
Wednesday, January 3, 2024
UnitedHealth Group, Microbiology, Growth, Cigna, Urinary tract infection, Medicare, Economics, PCR, Pharmaceutical industry

POUGHKEEPSIE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ -- Laboratory Economics has just released The U.S. Clinical Laboratory Industry: Forecast & Trends 2023-2025. With this special report, you can tap into 100+ pages of proprietary market research that reveals critical data and information about key business trends affecting the U.S. laboratory testing market.

Key Points: 
  • POUGHKEEPSIE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ -- Laboratory Economics has just released The U.S. Clinical Laboratory Industry: Forecast & Trends 2023-2025.
  • With this special report, you can tap into 100+ pages of proprietary market research that reveals critical data and information about key business trends affecting the U.S. laboratory testing market.
  • The report reveals that the U.S. laboratory testing market represented an estimated $125 billion of revenue in 2023 with a long-term annual growth rate of 3-4%.
  • The U.S. laboratory testing market faces multiple challenges, including post-pandemic employee wage inflation, greater utilization management and claims denials by private payers, and persistent reimbursement pressure.

Sharon Ward-Fore, MS, BS, MT(ASCP), CIC, FAPIC, honored with the Infection Control Today Educator of the Year Award™

Retrieved on: 
Tuesday, December 19, 2023
Online, Biology, Workforce, Multimedia, Microbiology, Infection, ASCP, Research, Disinfectant, ICT, IPS, Education, Heart, APIC, Love, CIC, IP, Nursing

Additionally, the individual must have done a superlative job in educating internal and external stakeholders about the importance of infection prevention.

Key Points: 
  • Additionally, the individual must have done a superlative job in educating internal and external stakeholders about the importance of infection prevention.
  • She started her career in an acute care hospital microbiology lab, then transitioned to industrial microbiology research and development.
  • Ward-Fore is an independent infection prevention consultant, a member of the editorial advisory board of the Infection Control Today journal, and a clinical editor for APIC Text Online.
  • Ward-Fore has a Bachelor of Science degree in biology and medical technology, a Master of Science degree in clinical microbiology, and is board-certified in infection control (CIC).

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

Retrieved on: 
Wednesday, December 13, 2023
Biology, CHR, Face, Novo, Carbon, Science, Microbiology, Creative industries

Hansen have announced that the name of the future combined company will be ‘Novonesis’.

Key Points: 
  • Hansen have announced that the name of the future combined company will be ‘Novonesis’.
  • Hansen announced their future name ‘Novonesis’.
  • Ester Baiget, President and CEO of Novozymes, said:
    “Novonesis reflects where we came from, what we can achieve, and what we will become together.
  • That is why we have chosen to call our new company Novonesis which means ‘A new beginning’.”
    “We developed the name Novonesis in close collaboration and dialogue between Novozymes and Chr.